These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 36503712)
1. Plasma sICAM-1 correlates with tumor volume before primary radiochemotherapy of head and neck squamous cell carcinoma patients. Clasen K; Welz S; Faltin H; Zips D; Eckert F Radiol Oncol; 2022 Dec; 56(4):501-507. PubMed ID: 36503712 [TBL] [Abstract][Full Text] [Related]
2. Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients. Clasen K; Welz S; Faltin H; Zips D; Eckert F Strahlenther Onkol; 2022 Feb; 198(2):194-200. PubMed ID: 34671818 [TBL] [Abstract][Full Text] [Related]
3. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". Schüttrumpf L; Marschner S; Scheu K; Hess J; Rietzler S; Walch A; Baumeister P; Kirchner T; Ganswindt U; Zitzelsberger H; Belka C; Maihoefer C Radiat Oncol; 2020 Jan; 15(1):7. PubMed ID: 31906998 [TBL] [Abstract][Full Text] [Related]
4. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy. Hilke FJ; Muyas F; Admard J; Kootz B; Nann D; Welz S; Rieß O; Zips D; Ossowski S; Schroeder C; Clasen K Radiother Oncol; 2020 Oct; 151():182-189. PubMed ID: 32687856 [TBL] [Abstract][Full Text] [Related]
5. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M; Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065 [TBL] [Abstract][Full Text] [Related]
6. Approximation of head and neck cancer volumes in contrast enhanced CT. Dejaco D; Url C; Schartinger VH; Haug AK; Fischer N; Riedl D; Posch A; Riechelmann H; Widmann G Cancer Imaging; 2015 Sep; 15():16. PubMed ID: 26419914 [TBL] [Abstract][Full Text] [Related]
7. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726 [TBL] [Abstract][Full Text] [Related]
8. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422 [TBL] [Abstract][Full Text] [Related]
9. Specific growth rates calculated from CTs in patients with head and neck squamous cell carcinoma: a retrospective study performed in Austria. Dejaco D; Steinbichler T; Schartinger VH; Fischer N; Anegg M; Dudas J; Posch A; Widmann G; Riechelmann H BMJ Open; 2019 Feb; 9(2):e025359. PubMed ID: 30782931 [TBL] [Abstract][Full Text] [Related]
10. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer. Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528 [TBL] [Abstract][Full Text] [Related]
12. Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. Schmidt S; Linge A; Grosser M; Lohaus F; Gudziol V; Nowak A; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baretton GB; Buchholz F; Baumann M; Krause M; Löck S; J Mol Diagn; 2020 Jun; 22(6):801-810. PubMed ID: 32247864 [TBL] [Abstract][Full Text] [Related]
13. Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas. Bohlen M; Busch C-; Sehner S; Forterre F; Bier J; Berliner C; Bußmann L; Münscher A Eur Arch Otorhinolaryngol; 2019 Apr; 276(4):1183-1189. PubMed ID: 30725209 [TBL] [Abstract][Full Text] [Related]
14. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG. Löck S; Linge A; Lohaus F; Ebert N; Gudziol V; Nowak A; Tinhofer I; Kalinauskaite G; Guberina M; Stuschke M; Balermpas P; von der Grün J; Grosu AL; Debus J; Ganswindt U; Belka C; Peeken JC; Combs SE; De-Colle C; Zips D; Baretton GB; Krause M; Baumann M; Radiother Oncol; 2022 Apr; 169():8-14. PubMed ID: 35182686 [TBL] [Abstract][Full Text] [Related]
15. [Serum concentrations of soluble adhesion molecules sICAM-1 and sVCAM-1 in patients with malignant ENT tumors]. Kaptur S; Riedel F; Erhardt T; Hörmann K HNO; 2001 Nov; 49(11):910-3. PubMed ID: 11759243 [TBL] [Abstract][Full Text] [Related]
16. Second-look PET-CT following an initial incomplete PET-CT response to (chemo)radiotherapy for head and neck squamous cell carcinoma. Prestwich RJD; Arunsingh M; Zhong J; Dyker KE; Vaidyanathan S; Scarsbrook AF Eur Radiol; 2020 Feb; 30(2):1212-1220. PubMed ID: 31485835 [TBL] [Abstract][Full Text] [Related]
18. Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma. Suzuki H; Kawasaki Y; Miura M; Hatakeyama H; Shina K; Suzuki S; Yamada T; Suzuki M; Ito A; Omori Y Asian Pac J Cancer Prev; 2022 Apr; 23(4):1271-1278. PubMed ID: 35485685 [TBL] [Abstract][Full Text] [Related]
19. Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy. Mollnar S; Pondorfer P; Kasparek AK; Reinisch S; Moik F; Stotz M; Halm M; Szkandera J; Terbuch A; Eisner F; Gerger A; Kapp KS; Partl R; Vasicek S; Weiland T; Pichler M; Stöger H; Thurnher D; Posch F Clin Transl Oncol; 2021 Mar; 23(3):543-553. PubMed ID: 32671728 [TBL] [Abstract][Full Text] [Related]
20. The Utility of Ultrasonography in the Diagnosis of Cervical Lymph Nodes after Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma. Terada H; Shimode Y; Furukawa M; Sato Y; Hanai N Medicina (Kaunas); 2021 Apr; 57(5):. PubMed ID: 33922457 [No Abstract] [Full Text] [Related] [Next] [New Search]